Anti-gonadotrophin releasing hormone vaccine - ML Laboratories/Protherics

Drug Profile

Anti-gonadotrophin releasing hormone vaccine - ML Laboratories/Protherics

Alternative Names: GnRH immunotherapeutic; GnRH vaccine - ML Laboratories/Protherics; GnRHi; O14L; PM-OV-92; Prolog

Latest Information Update: 22 Jun 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protherics
  • Class Antiandrogens; Antiprogestogens; Vaccines
  • Mechanism of Action Estrogen receptor antagonists; Gonadotropin releasing hormone inhibitors; Immunostimulants; Progesterone receptor antagonists; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 22 Jun 2004 Discontinued - Phase-II for Prostate cancer in United Kingdom (unspecified route)
  • 09 Jul 2001 Preliminary results of a phase II trial revealed that GnRHi did not elicit large reductions in testosterone levels and ML Laboratories may be about to discontinue the vaccine's development
  • 01 Sep 2000 A phase II study of the new formulation of Prolog® in patients with late-stage prostate cancer is underway in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top